AIM: To investigate whether Tg737 is regulated by microRNA-548a-5p (miR-548a-5p), and correlates with hepatocellular carcinoma (HCC) cell proliferation and apoptosis. METHODS: Assays of loss of function of Tg737 were performed by the colony formation assay, CCK assay and cell cycle assay in HCC cell lines. The interaction between miR-548a-5p and its downstream target, Tg737, was evaluated by a dual-luciferase reporter assay and quantitative real-time polymerase chain reaction. Tg737 was then up-regulated in HCC cells to evaluate its effect on miR-548a-5p regulation. HepG2 cells stably overexpressing miR-548a-5p or miR-control were also subcutaneously inoculated into nude mice to evaluate the effect of miR-548a-5p up-regulation on in vivo tumor growth. As the final step, the effect of miR-548a-5p on the apoptosis induced by cisplatin was evaluated by flow cytometry. RESULTS: Down-regulation of Tg737, which is a target gene of miR-548a-5p, accelerated HCC cell proliferation, and miR-548a-5p promoted HCC cell proliferation in vitro and in vivo. Like the down-regulation of Tg737, overexpression of miR-548a-5p in HCC cell lines promoted cell proliferation, increased colony forming ability and hampered cell apoptosis. In addition, miR-548a-5p overexpression increased HCC cell growth in vivo. MiR-548a-5p down-regulated Tg737 expression through direct contact with its 3' untranslated region (UTR), and miR-548a-5p expression was negatively correlated with Tg737 levels in HCC specimens. Restoring Tg737 (without the 3'UTR) significantly hampered miR-548a-5p induced cell proliferation, and rescued the miR-548a-5p induced cell proliferation inhibition and apoptosis induced by cisplatin. CONCLUSION: MiR-548a-5p negatively regulates the tumor inhibitor gene Tg737 and promotes tumorigenesis in vitro and in vivo, indicating its potential as a novel therapeutic target for HCC.
AIM: To investigate whether Tg737 is regulated by microRNA-548a-5p (miR-548a-5p), and correlates with hepatocellular carcinoma (HCC) cell proliferation and apoptosis. METHODS: Assays of loss of function of Tg737 were performed by the colony formation assay, CCK assay and cell cycle assay in HCC cell lines. The interaction between miR-548a-5p and its downstream target, Tg737, was evaluated by a dual-luciferase reporter assay and quantitative real-time polymerase chain reaction. Tg737 was then up-regulated in HCC cells to evaluate its effect on miR-548a-5p regulation. HepG2 cells stably overexpressing miR-548a-5p or miR-control were also subcutaneously inoculated into nude mice to evaluate the effect of miR-548a-5p up-regulation on in vivo tumor growth. As the final step, the effect of miR-548a-5p on the apoptosis induced by cisplatin was evaluated by flow cytometry. RESULTS: Down-regulation of Tg737, which is a target gene of miR-548a-5p, accelerated HCC cell proliferation, and miR-548a-5p promoted HCC cell proliferation in vitro and in vivo. Like the down-regulation of Tg737, overexpression of miR-548a-5p in HCC cell lines promoted cell proliferation, increased colony forming ability and hampered cell apoptosis. In addition, miR-548a-5p overexpression increased HCC cell growth in vivo. MiR-548a-5p down-regulated Tg737 expression through direct contact with its 3' untranslated region (UTR), and miR-548a-5p expression was negatively correlated with Tg737 levels in HCC specimens. Restoring Tg737 (without the 3'UTR) significantly hampered miR-548a-5p induced cell proliferation, and rescued the miR-548a-5p induced cell proliferation inhibition and apoptosis induced by cisplatin. CONCLUSION:MiR-548a-5p negatively regulates the tumor inhibitor gene Tg737 and promotes tumorigenesis in vitro and in vivo, indicating its potential as a novel therapeutic target for HCC.
Authors: R J Isfort; D B Cody; C J Doersen; W G Richards; B K Yoder; J E Wilkinson; L D Kier; R L Jirtle; J S Isenberg; J E Klounig; R P Woychik Journal: Oncogene Date: 1997-10-09 Impact factor: 9.867
Authors: Manveen K Gupta; Carmel Halley; Zhong-Hui Duan; Jason Lappe; Jamie Viterna; Subhra Jana; Katarzyna Augoff; Maradumane L Mohan; Neelakantan T Vasudevan; Jie Na; Khalid Sossey-Alaoui; Xiuping Liu; Chang-Gong Liu; W H Wilson Tang; Sathyamangla V Naga Prasad Journal: J Mol Cell Cardiol Date: 2013-06-02 Impact factor: 5.000
Authors: G J Pazour; B L Dickert; Y Vucica; E S Seeley; J L Rosenbaum; G B Witman; D G Cole Journal: J Cell Biol Date: 2000-10-30 Impact factor: 10.539
Authors: Hyun Chang; Nayoung Kim; Ji Hyun Park; Ryoung Hee Nam; Yoon Jeong Choi; Hye Seung Lee; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Jung Min Kim; Dong Ho Lee Journal: Gut Liver Date: 2015-03 Impact factor: 4.519
Authors: Roopa Siddaiah; Lucy Emery; Heather Stephens; Ann Donnelly; Jennifer Erkinger; Kimberly Wisecup; Steven D Hicks; Yuka Imamura Kawasawa; Christiana Oji-Mmuo; Shaili Amatya; Patricia Silveyra Journal: Life (Basel) Date: 2022-03-30
Authors: William M MacCuaig; Alexandra Thomas; Juan C Claros-Sorto; Jorge G Gomez-Gutierrez; Adam C Alexander; Elizabeth A Wellberg; William E Grizzle; Lacey R McNally Journal: Biotech Histochem Date: 2022-01-04 Impact factor: 1.834